GBI Research Market Research Reports

TITLE Actions
Osteoporosis Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by ongoing Transition from Anti-resorptive Agents to Anabolic Therapies, Rising Prevalence, and Growing Awareness
Published in Aug 2018 | US $ 4995 Onwards | By GBI Research

Summary Osteoporosis is a “silent epidemic” and as per the WHO declarations, it is a priority health issue. Osteoporosis is a disruption of bone architecture and decrease in bone mass, leading to a number of co...

Respiratory Tract Infections Drug Development Pipeline Review, 2018
Published in Jul 2018 | US $ 3995 Onwards | By GBI Research

Respiratory Tract Infections Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeuti...

Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018
Published in Jul 2018 | US $ 3995 Onwards | By GBI Research

Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for mucopolysaccharidosis disorders, a group of inherited lysosomal storage disorders....

Diarrhea and Constipation Drug Development Pipeline Review, 2018
Published in Jul 2018 | US $ 3995 Onwards | By GBI Research

Diarrhea and Constipation Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for diarrhea and constipation. It provides comprehensive information on the therapeutics und...

Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer
Published in Jul 2018 | US $ 6995 Onwards | By GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer Summary Breast cancer remains a major global healthcare concern despi...

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline
Published in Jul 2018 | US $ 4995 Onwards | By GBI Research

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form...

Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018
Published in Jun 2018 | US $ 3995 Onwards | By GBI Research

Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensi...

Menopausal Disorders Drug Development Pipeline Review, 2018
Published in Jun 2018 | US $ 3995 Onwards | By GBI Research

Menopausal Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under develop...

Hepatitis Drug Development Pipeline Review, 2018
Published in Jun 2018 | US $ 3995 Onwards | By GBI Research

Hepatitis Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and ke...

Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market
Published in Jun 2018 | US $ 4995 Onwards | By GBI Research

Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the world’s population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common sy...

Mosquito-borne Diseases Drug Development Pipeline Review, 2018
Published in May 2018 | US $ 3995 Onwards | By GBI Research

Mosquito-borne Diseases Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under developmen...

Ocular Cancer Drug Development Pipeline Review, 2018
Published in May 2018 | US $ 3995 Onwards | By GBI Research

Ocular Cancer Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for ocular cancer and comprehensive information on the therapeutics under development and key players in...

Inflammatory Skin Diseases Drug Development Pipeline Review, 2018
Published in May 2018 | US $ 3995 Onwards | By GBI Research

Inflammatory Skin Diseases Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for inflammatory skin disorders and comprehensive information on the therapeutics under dev...

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms
Published in May 2018 | US $ 6995 Onwards | By GBI Research

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia is a chronic mental disorder that affects 1% of the population - equivalen...

Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence
Published in May 2018 | US $ 4995 Onwards | By GBI Research

Breast cancer is the second most common cancer in the world overall, and the most common cancer in women. When diagnosed at a very early stage, the prognosis is positive, with a five-year survival rate of nearly 90%. However, in the later stages o...

Influenza A Viral Infections Drug Development Pipeline Review, 2018
Published in Apr 2018 | US $ 3995 Onwards | By GBI Research

This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1...

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018
Published in Apr 2018 | US $ 3995 Onwards | By GBI Research

This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3). It provides comprehensive information on the therapeutics under dev...

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018
Published in Apr 2018 | US $ 3995 Onwards | By GBI Research

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therap...

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease
Published in Apr 2018 | US $ 6995 Onwards | By GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease Summary ...

HAE Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Ongoing Shift towards Plasma-Derivative Products and Expected Launch of Premium Therapies
Published in Mar 2018 | US $ 4995 Onwards | By GBI Research

Hereditary Angioedema (HAE) is a rare genetic disorder caused by a lack of a sufficient amount of a protein called C1 esterase inhibitor (C1-INH), which plays a role in immune system function, blood clotting, and bleeding. With insufficient C1-INH...

We are on:

Need Help?